Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine add-on trial in hospitalized patients with schizophrenia
IRCT20190707044123N1Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of famotidine in schizophrenia (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Symptoms of schizophrenic patients and Memory function. Started Jul 2019; status: completed.
02
Drugs
famotidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20190707044123N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190707044123N1.